News
ENZC
0.0003
0.00%
0.0000
Weekly Report: what happened at ENZC last week (1208-1212)?
Weekly Report · 3d ago
Weekly Report: what happened at ENZC last week (1201-1205)?
Weekly Report · 12/08 09:58
Weekly Report: what happened at ENZC last week (1124-1128)?
Weekly Report · 12/01 09:55
Weekly Report: what happened at ENZC last week (1117-1121)?
Weekly Report · 11/24 09:59
Weekly Report: what happened at ENZC last week (1110-1114)?
Weekly Report · 11/17 09:59
Weekly Report: what happened at ENZC last week (1103-1107)?
Weekly Report · 11/10 09:57
Weekly Report: what happened at ENZC last week (1027-1031)?
Weekly Report · 11/03 09:57
Weekly Report: what happened at ENZC last week (1020-1024)?
Weekly Report · 10/27 09:59
Weekly Report: what happened at ENZC last week (1013-1017)?
Weekly Report · 10/20 09:57
Weekly Report: what happened at ENZC last week (1006-1010)?
Weekly Report · 10/13 09:59
Weekly Report: what happened at ENZC last week (0929-1003)?
Weekly Report · 10/06 09:56
Weekly Report: what happened at ENZC last week (0922-0926)?
Weekly Report · 09/29 09:57
Weekly Report: what happened at ENZC last week (0915-0919)?
Weekly Report · 09/22 09:57
Weekly Report: what happened at ENZC last week (0908-0912)?
Weekly Report · 09/15 11:24
Weekly Report: what happened at ENZC last week (0901-0905)?
Weekly Report · 09/08 11:27
Weekly Report: what happened at ENZC last week (0825-0829)?
Weekly Report · 09/01 11:21
Weekly Report: what happened at ENZC last week (0818-0822)?
Weekly Report · 08/25 11:33
Weekly Report: what happened at ENZC last week (0811-0815)?
Weekly Report · 08/18 11:24
Weekly Report: what happened at ENZC last week (0804-0808)?
Weekly Report · 08/11 11:33
Weekly Report: what happened at ENZC last week (0728-0801)?
Weekly Report · 08/04 11:35
More
Webull provides a variety of real-time ENZC stock news. You can receive the latest news about Enzolytics through multiple platforms. This information may help you make smarter investment decisions.
About ENZC
Enzolytics, Inc. is a drug development company. The Company is focused on commercializing its licensed proprietary proteins and monoclonal antibodies to treat debilitating infectious diseases to include the additional contracted areas of sales, marketing and distribution of medical devices, medical testing and nutraceutical products. Its subsidiaries include BioClonetics lmmunotherapy, Inc. and Biogenysis, Inc.